Title, Synopsis and Publications Investigators and Collaborators
Use and costs of a polypill for primary and secondary prevention of cardiovascular disease in Australian women.
As the population ages, the availability of a combination cardio-protective “polypill” has the potential to increase chemoprophylaxis coverage for primary and secondary prevention of cardiovascular disease (CVD), and substantially reduce costs to both governments and consumers. This study identifies the likely change in CVD medication costs for mid- and older-aged Australian women, if a simple fixed low-dose low-cost polypill were to be given to everyone older than 55 years, regardless of their CVD risk profile.
Publications: 589  
Return
Prof Julie Byles
Dr Jennifer Stewart Williams
Prof Chris Doran
Dr Chris Wallick
Dr Andrew Searles
Dr Paul Kowal
Dr Xenia Dolja-Gore
Ms Healther Hestekin
Mr Tristan O'Driscoll